The RET-targeted anticancer therapy ‘Retevmo’ may now be prescribed at the Big 5 hospitals in Korea.

According to industry sources, Lilly Korea’s Retevmo (selpercatinib) passed the drug committees of all the Big 5 tertiary hospitals in Korea - Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary’s Hospital, Seoul Asan Medical Center, and Sinchon Severance Hospital.

As the drug is undergoing drug pricing negotiations with the National Health Insurance Service, the drug is expected to be readily prescribed if it passes reimbursement. Whether the first targeted RET mutation-targeted anticancer drug option will be born remains to be seen.

Retevmo, w